Telomere length is an independent prognostic marker in MDS but not in de novo AML

British Journal of Haematology

Volumn 178, Issue 2, 2017, Pages 240-249

  Williams, Jenna ^a   Heppel, Nicole H ^a   Britt Compton, Bethan ^a   Grimstead, Julia W ^a   Jones, Rhiannon E ^a   Tauro, Sudhir ^b   Bowen, David T ^c   Knapper, Steven ^a   Groves, Michael ^b   Hills, Robert K ^a   Pepper, Chris ^a   Baird, Duncan M ^a   Fegan, Chris ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b NINEWELLS HOSPITAL   (United Kingdom)

^c ST JAMES S INSTITUTE OF ONCOLOGY   (United Kingdom)

Author keywords

AML; myelodysplasia; telomerase; telomere

Indexed keywords

TELOMERASE; TUMOR MARKER;

ACUTE MYELOID LEUKEMIA; ADULT; AGED; DISEASE FREE SURVIVAL; ENZYMOLOGY; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MYELODYSPLASTIC SYNDROME; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; TELOMERE; YOUNG ADULT;

ADULT; AGED; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; TELOMERASE; TELOMERE; YOUNG ADULT;

EID: 85019146305     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.14666     Document Type: Article

References (43)

1. Aalbers, A.M., Calado, R.T., Young, N.S., Zwaan, C.M., Wu, C., Kajigaya, S., Coenen, E.A., Baruchel, A., Geleijns, K., de Haas, V., Kaspers, G.J., Kuijpers, T.W., Reinhardt, D., Trka, J., Zimmermann, M., Pieters, R., van der Velden, V.H. & van den Heuvel-Eibrink, M.M. (2013) Telomere length and telomerase complex mutations in pediatric acute myeloid leukemia. Leukemia, 27, 1786–1789.
2. Baird, D.M., Rowson, J., Wynford-Thomas, D. & Kipling, D. (2003) Extensive allelic variation and ultrashort telomeres in senescent human cells. Nature Genetics, 33, 203–207.
3. Ballew, B.J. & Savage, S.A. (2013) Updates on the biology and management of dyskeratosis congenita and related telomere biology disorders. Expert Review of Hematology, 6, 327–337.
4. Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R.L., Neuberg, D. & Ebert, B.L. (2011) Clinical effect of point mutations in myelodysplastic syndromes. The New England Journal of Medicine, 364, 2496–2506.
5. Boultwood, J., Fidler, C., Kusec, R., Rack, K., Elliott, P.J., Atoyebi, O., Chapman, R., Oscier, D.G. & Wainscoat, J.S. (1997) Telomere length in myelodysplastic syndromes. American Journal of Hematology, 56, 266–271.
6. Britt-Compton, B., Lin, T.T., Ahmed, G., Weston, V., Jones, R.E., Fegan, C., Oscier, D.G., Stankovic, T., Pepper, C. & Baird, D.M. (2012) Extreme telomere erosion in ATM-mutated and 11q-deleted CLL patients is independent of disease stage. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K., 26, 826–830.
7. Calado, R.T., Regal, J.A., Hills, M., Yewdell, W.T., Dalmazzo, L.F., Zago, M.A., Lansdorp, P.M., Hogge, D., Chanock, S.J., Estey, E.H., Falcao, R.P. & Young, N.S. (2009) Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 106, 1187–1192.
8. Chakraborty, S., Sun, C.L., Francisco, L., Sabado, M., Li, L., Chang, K.L., Forman, S., Bhatia, S. & Bhatia, R. (2009) Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 27, 791–798.
9. Colla, S., Ong, D.S., Ogoti, Y., Marchesini, M., Mistry, N.A., Clise-Dwyer, K., Ang, S.A., Storti, P., Viale, A., Giuliani, N., Ruisaard, K., Ganan Gomez, I., Bristow, C.A., Estecio, M., Weksberg, D.C., Ho, Y.W., Hu, B., Genovese, G., Pettazzoni, P., Multani, A.S., Jiang, S., Hua, S., Ryan, M.C., Carugo, A., Nezi, L., Wei, Y., Yang, H., D'Anca, M., Zhang, L., Gaddis, S., Gong, T., Horner, J.W., Heffernan, T.P., Jones, P., Cooper, L.J., Liang, H., Kantarjian, H., Wang, Y.A., Chin, L., Bueso-Ramos, C., Garcia-Manero, G. & DePinho, R.A. (2015) Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome. Cancer Cell, 27, 644–657.
10. Daniali, L., Benetos, A., Susser, E., Kark, J.D., Labat, C., Kimura, M., Desai, K., Granick, M. & Aviv, A. (2013) Telomeres shorten at equivalent rates in somatic tissues of adults. Nature Communications, 4, 1597.
11. Engelhardt, M., Wasch, R. & Guo, Y. (2004) Telomeres and telomerase in normal and leukemic hematopoietic cells. Leukemia Research, 28, 1001–1004.
12. Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., Bigerna, B., Pacini, R., Pucciarini, A., Liso, A., Vignetti, M., Fazi, P., Meani, N., Pettirossi, V., Saglio, G., Mandelli, F., Lo-Coco, F., Pelicci, P.G. & Martelli, M.F. (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. The New England Journal of Medicine, 352, 254–266.
13. Gadji, M., Adebayo Awe, J., Rodrigues, P., Kumar, R., Houston, D.S., Klewes, L., Dieye, T.N., Rego, E.M., Passetto, R.F., de Oliveira, F.M. & Mai, S. (2012) Profiling three-dimensional nuclear telomeric architecture of myelodysplastic syndromes and acute myeloid leukemia defines patient subgroups. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 18, 3293–3304.
14. Genovese, G., Kahler, A.K., Handsaker, R.E., Lindberg, J., Rose, S.A., Bakhoum, S.F., Chambert, K., Mick, E., Neale, B.M., Fromer, M., Purcell, S.M., Svantesson, O., Landen, M., Hoglund, M., Lehmann, S., Gabriel, S.B., Moran, J.L., Lander, E.S., Sullivan, P.F., Sklar, P., Gronberg, H., Hultman, C.M. & McCarroll, S.A. (2014) Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. The New England Journal of Medicine, 371, 2477–2487.
15. Greenberg, P.L. (1998) Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. Leukemia Research, 22, 1123–1136.
16. Greenberg, P. (1999) Apoptosis and its role in myelodyslastic syndrome. Leukemia Research, 23, 855.
17. Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. & Bennett, J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079–2088.
18. Greenberg, P.L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Sole, F., Bennett, J.M., Bowen, D., Fenaux, P., Dreyfus, F., Kantarjian, H., Kuendgen, A., Levis, A., Malcovati, L., Cazzola, M., Cermak, J., Fonatsch, C., Le Beau, M.M., Slovak, M.L., Krieger, O., Luebbert, M., Maciejewski, J., Magalhaes, S.M., Miyazaki, Y., Pfeilstocker, M., Sekeres, M., Sperr, W.R., Stauder, R., Tauro, S., Valent, P., Vallespi, T., van de Loosdrecht, A.A., Germing, U. & Haase, D. (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood, 120, 2454–2465.
19. Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P.V., Mar, B.G., Lindsley, R.C., Mermel, C.H., Burtt, N., Chavez, A., Higgins, J.M., Moltchanov, V., Kuo, F.C., Kluk, M.J., Henderson, B., Kinnunen, L., Koistinen, H.A., Ladenvall, C., Getz, G., Correa, A., Banahan, B.F., Gabriel, S., Kathiresan, S., Stringham, H.M., McCarthy, M.I., Boehnke, M., Tuomilehto, J., Haiman, C., Groop, L., Atzmon, G., Wilson, J.G., Neuberg, D., Altshuler, D. & Ebert, B.L. (2014) Age-related clonal hematopoiesis associated with adverse outcomes. The New England Journal of Medicine, 371, 2488–2498.
20. Jones, C.H., Pepper, C. & Baird, D.M. (2012) Telomere dysfunction and its role in haematological cancer. British Journal of Haematology, 156, 573–587.
21. Kirwan, M., Beswick, R., Vulliamy, T., Nathwani, A.C., Walne, A.J., Casimir, C. & Dokal, I. (2009) Exogenous TERC alone can enhance proliferative potential, telomerase activity and telomere length in lymphocytes from dyskeratosis congenita patients. British Journal of Haematology, 144, 771–781.
22. Kottaridis, P.D., Gale, R.E., Frew, M.E., Harrison, G., Langabeer, S.E., Belton, A.A., Walker, H., Wheatley, K., Bowen, D.T., Burnett, A.K., Goldstone, A.H. & Linch, D.C. (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood, 98, 1752–1759.
23. Lin, T.T., Letsolo, B.T., Jones, R.E., Rowson, J., Pratt, G., Hewamana, S., Fegan, C., Pepper, C. & Baird, D.M. (2010) Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis. Blood, 116, 1899–1907.
24. Lin, T.T., Norris, K., Heppel, N.H., Pratt, G., Allan, J.M., Allsup, D.J., Bailey, J., Cawkwell, L., Hills, R., Grimstead, J.W., Jones, R.E., Britt-Compton, B., Fegan, C., Baird, D.M. & Pepper, C. (2014) Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. British Journal of Haematology, 167, 214–223.
25. McKerrell, T. & Vassiliou, G.S. (2015) Aging as a driver of leukemogenesis. Science Translational Medicine, 7, 306 fs338.
26. McKerrell, T., Park, N., Moreno, T., Grove, C.S., Ponstingl, H., Stephens, J., Crawley, C., Craig, J., Scott, M.A., Hodkinson, C., Baxter, J., Rad, R., Forsyth, D.R., Quail, M.A., Zeggini, E., Ouwehand, W., Varela, I. & Vassiliou, G.S. (2015) Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. Cell Reports, 10, 1239–1245.
27. Ohyashiki, J.H., Iwama, H., Yahata, N., Ando, K., Hayashi, S., Shay, J.W. & Ohyashiki, K. (1999) Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 5, 1155–1160.
28. Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T. & Carbone, PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology, 5, 649–655.
29. Papaemmanuil, E., Gerstung, M., Malcovati, L., Tauro, S., Gundem, G., Van Loo, P., Yoon, C.J., Ellis, P., Wedge, D.C., Pellagatti, A., Shlien, A., Groves, M.J., Forbes, S.A., Raine, K., Hinton, J., Mudie, L.J., McLaren, S., Hardy, C., Latimer, C., Della Porta, M.G., O'Meara, S., Ambaglio, I., Galli, A., Butler, A.P., Walldin, G., Teague, J.W., Quek, L., Sternberg, A., Gambacorti-Passerini, C., Cross, N.C., Green, A.R., Boultwood, J., Vyas, P., Hellstrom-Lindberg, E., Bowen, D., Cazzola, M., Stratton, M.R., Campbell, P.J.; Chronic Myeloid Disorders Working Group of the International Cancer Genome, C. (2013) Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood, 122, 3616–3627; quiz 3699.
30. Parker, J.E. & Mufti, G.J. (2000) Excessive apoptosis in low risk myelodysplastic syndromes (MDS). Leukemia & Lymphoma, 40, 1–24.
31. Parker, J.E., Fishlock, K.L., Mijovic, A., Czepulkowski, B., Pagliuca, A. & Mufti, G.J. (1998) ‘Low-risk’ myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins. British Journal of Haematology, 103, 1075–1082.
32. Raza, A., Alvi, S., Borok, R.Z., Span, L., Parcharidou, A., Alston, D., Rifkin, S., Robin, E., Shah, R. & Gregory, S.A. (1997a) Excessive proliferation matched by excessive apoptosis in myelodysplastic syndromes: the cause-effect relationship. Leukemia & Lymphoma, 27, 111–118.
33. Raza, A., Alvi, S., Broady-Robinson, L., Showel, M., Cartlidge, J., Mundle, S.D., Shetty, V.T., Borok, R.Z., Dar, S.E., Chopra, H.K., Span, L., Parcharidou, A., Hines, C., Gezer, S., Venugopal, P., Loew, J., Showel, J., Alston, D., Hernandez, B., Rifkin, S., Robin, E., Shah, R. & Gregory, S.A. (1997b) Cell cycle kinetic studies in 68 patients with myelodysplastic syndromes following intravenous iodo- and/or bromodeoxyuridine. Experimental Hematology, 25, 530–535.
34. Roger, L., Jones, R.E., Heppel, N.H., Williams, G.T., Sampson, J.R. & Baird, D.M. (2013) Extensive telomere erosion in the initiation of colorectal adenomas and its association with chromosomal instability. Journal of the National Cancer Institute, 105, 1202–1211.
35. Shay, J.W. & Wright, W.E. (2011) Role of telomeres and telomerase in cancer. Seminars in Cancer Biology, 21, 349–353.
36. Sieglova, Z., Zilovcova, S., Cermak, J., Rihova, H., Brezinova, D., Dvorakova, R., Markova, M., Maaloufova, J., Sajdova, J., Brezinova, J., Zemanova, Z. & Michalova, K. (2004) Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: a marker of disease prognosis? Leukemia Research, 28, 1013–1021.
37. Tothova, Z., Steensma, D.P. & Ebert, B.L. (2013) New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice. Clinical Cancer Research, 19, 1637–1643.
38. Townsley, D.M., Dumitriu, B. & Young, N.S. (2014) Bone marrow failure and the telomeropathies. Blood, 124, 2775–2783.
39. Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., Harris, N.L., Le Beau, M.M., Hellstrom-Lindberg, E., Tefferi, A. & Bloomfield, C.D. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114, 937–951.
40. Walter, M.J., Shen, D., Ding, L., Shao, J., Koboldt, D.C., Chen, K., Larson, D.E., McLellan, M.D., Dooling, D., Abbott, R., Fulton, R., Magrini, V., Schmidt, H., Kalicki-Veizer, J., O'Laughlin, M., Fan, X., Grillot, M., Witowski, S., Heath, S., Frater, J.L., Eades, W., Tomasson, M., Westervelt, P., DiPersio, J.F., Link, D.C., Mardis, E.R., Ley, T.J., Wilson, R.K. & Graubert, T.A. (2012) Clonal architecture of secondary acute myeloid leukemia. The New England Journal of Medicine, 366, 1090–1098.
41. Xie, M., Lu, C., Wang, J., McLellan, M.D., Johnson, K.J., Wendl, M.C., McMichael, J.F., Schmidt, H.K., Yellapantula, V., Miller, C.A., Ozenberger, B.A., Welch, J.S., Link, D.C., Walter, M.J., Mardis, E.R., Dipersio, J.F., Chen, F., Wilson, R.K., Ley, T.J. & Ding, L. (2014) Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nature Medicine, 20, 1472–1478.
42. Yamaguchi, H., Baerlocher, G.M., Lansdorp, P.M., Chanock, S.J., Nunez, O., Sloand, E. & Young, N.S. (2003) Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood, 102, 916–918.
43. Young, N.S. (2010) Telomere biology and telomere diseases: implications for practice and research. Hematology/the Education Program of the American Society of Hematology American Society of Hematology. Education Program, 2010, 30–35.